S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48%
Next Bullish Trade
Sign in
SGMT

Sagimet Biosciences Inc. - Seri SGMT

$7.82 +0.17 (+2.22%)
Neutral · +0.88σ
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · SGMT

Momentum reads · latest daily bar
Last
$7.82
+0.17 (+2.22%)
Mkt cap
$483M
Healthcare
RSI(14)
58.7
neutral
Stochastic %K
81.4
overbought
MFI(14)
56.3
neutral
ADX(14)
17.0
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 — $-0.0B $-0.0B $-0.0B — —
2025-12-31 — $-0.0B $-0.0B $-0.0B — —
2025-09-30 — $-0.0B $-0.0B $-0.0B — —
2025-06-30 — $-0.0B $-0.0B $-0.0B — —
2025-03-31 — $-0.0B $-0.0B $-0.0B — —

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare SGMT vs peers

Line SGMT up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing SGMT no peers yet — add up to 4 below
Sector peers + LLY + UNH + JNJ + MRK + ABBV + PFE
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP

Add tickers to compare with SGMT

~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.

Earnings replay · last 11 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-12 -0.33 -0.35 +5.0% -0.7%
2026-03-11 -0.29 -0.40 +27.8% -7.0%
2025-11-13 -0.40 -0.39 -2.2% +0.1%
2025-08-13 -0.32 -0.50 +35.5% -9.5%
2025-05-08 -0.56 -0.69 +18.5% +1.9%
2025-03-12 -0.50 -0.59 +14.6% +0.0%
2024-11-14 -0.45 -0.40 -11.2% -8.7%
2024-08-14 -0.25 -0.35 +29.0% +11.7%
2024-05-15 -0.23 -0.38 +39.9% +2.8%
2023-11-13 -0.35 -0.80 +56.1% +13.0%
2023-08-21 -35.80 -0.52 -6829.0% -13.7%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
SGMT ★ $0B — -6.0 — — 2.5 — — — -5.63%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 25.96%

HolderShares% out
Vanguard Capital Management LLC 1,098,919 3.43%
Woodline Partners LP 1,000,943 3.13%
Marshall Wace LLP 966,253 3.02%
Baker Bros. Advisors, LP 952,996 2.98%
Affinity Asset Advisors, Llc 868,020 2.71%
Millennium Management Llc 862,303 2.69%
Blackrock Inc. 799,943 2.50%
HHLR Advisors, LTD 724,800 2.26%
Renaissance Technologies, LLC 625,469 1.95%
Shaw D.E. & Co., Inc. 411,570 1.29%

Insider activity · 90d

11 buys / 0 sells · ratio 11.0 · Finnhub

  • Hoelscher Paul W. BUY 39,567
  • Jarrett Jennifer BUY 39,567
  • Kemble George BUY 39,567
  • Phillips Anne M. BUY 39,567
  • GRAMMER ELIZABETH A BUY 39,567
  • SEIDENBERG BETH C BUY 39,567
  • Chauche Thierry BUY 50,000
  • Grauer Andreas BUY 35,000
  • Rozek Elizabeth BUY 100,000
  • Happel David BUY 300,000

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$8.0
Mean
$26.2
High
$49.0
Analysts
10
Recommendation distribution · period 2026-07-01
6
10
2
Revision trend (2026-04-01 → 2026-07-01): net 16 → 16 0 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
4 2026-06-15 OWNERSHIP DOCUMENT view ·
8-K 2026-06-12 FORM 8-K view ·
8-K 2026-06-03 FORM 8-K view ·
4 2026-06-01 OWNERSHIP DOCUMENT view ·
4 2026-06-01 OWNERSHIP DOCUMENT view ·
4 2026-06-01 OWNERSHIP DOCUMENT view ·
4 2026-06-01 OWNERSHIP DOCUMENT view ·
4 2026-05-14 OWNERSHIP DOCUMENT view ·
8-K 2026-05-12 FORM 8-K view ·
10-Q 2026-05-12 10-Q view ·
8-K 2026-04-28 FORM 8-K view ·
8-K 2026-04-27 FORM 8-K view ·
8-K 2026-04-27 FORM 8-K view ·
DEF 14A 2026-04-21 DEF 14A view ·
8-K 2026-04-21 FORM 8-K view ·
8-K 2026-03-11 FORM 8-K view ·
10-K 2026-03-11 10-K view ·
4 2026-02-20 OWNERSHIP DOCUMENT view ·
4 2026-02-20 OWNERSHIP DOCUMENT view ·
4 2026-02-20 OWNERSHIP DOCUMENT view ·
4 2026-02-20 OWNERSHIP DOCUMENT view ·
4 2026-02-12 OWNERSHIP DOCUMENT view ·
4 2026-02-12 OWNERSHIP DOCUMENT view ·
4 2026-02-12 OWNERSHIP DOCUMENT view ·
4 2026-02-12 OWNERSHIP DOCUMENT view ·
8-K 2026-02-02 FORM 8-K view ·
8-K 2025-12-18 FORM 8-K view ·
8-K 2025-12-17 FORM 8-K view ·
4 2025-11-21 OWNERSHIP DOCUMENT view ·
8-K 2025-11-13 FORM 8-K view ·
10-Q 2025-11-13 10-Q view ·
4 2025-11-06 OWNERSHIP DOCUMENT view ·
8-K 2025-10-23 FORM 8-K view ·
8-K 2025-08-22 FORM 8-K view ·
8-K 2025-08-14 FORM 8-K view ·
8-K 2025-08-13 FORM 8-K view ·
10-Q 2025-08-13 10-Q view ·
4 2025-07-23 OWNERSHIP DOCUMENT view ·
4 2025-07-23 OWNERSHIP DOCUMENT view ·
4 2025-07-23 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
4 2025-06-10 OWNERSHIP DOCUMENT view ·
8-K 2025-06-10 FORM 8-K view ·
8-K 2025-06-04 FORM 8-K view ·
8-K 2025-05-08 FORM 8-K view ·
10-Q 2025-05-08 10-Q view ·
8-K 2025-04-30 FORM 8-K view ·
DEF 14A 2025-04-30 DEF 14A view ·
8-K 2025-03-12 FORM 8-K view ·
10-K 2025-03-12 10-K view ·

About SGMT

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Options picks · SGMT

ITM + OTM ideas from the latest scan

Loading…

Congress trades · SGMT

STOCK Act disclosures

Loading…

SEC filings & insiders · SGMT

EDGAR · live

Loading…

Holders · SGMT

Institutions & insider activity

Loading…